What is C-PN's earnings per share (EPS)?

C-PN (C-PN) reported diluted earnings per share of $6.99 for fiscal year 2025. This represents a 17.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

C-PN Financials

C-PN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows C-PN (C-PN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI C-PN FY2025 2026-04-22

Thin returns on a huge balance sheet are being supported by liability-funded growth rather than consistent internal cash generation.

From FY2023 through FY2025, net income stayed positive at $9.2B to $14.3B while operating cash flow stayed negative at -$73.4B to -$67.6B; that gap means reported profitability was accompanied by balance-sheet movements that consumed cash instead of releasing it. In FY2025, cash still rose to $349.6B only because financing inflows of $238.0B outweighed both operating and investing outflows.

This is a business where return on assets was only 0.5% in FY2025, yet return on equity reached 6.7%; shareholder returns are being amplified by leverage rather than by high earnings per dollar of assets. With $2.44T of liabilities against $212.3B of equity, even small shifts in asset profitability can have an outsized effect on equity results.

FY2025 balance-sheet expansion was almost entirely liability-funded: assets increased by about $304.3B while equity rose only $3.7B. At the same time, shares outstanding fell from 1.91B in FY2023 to 1.75B in FY2025, so per-share improvement was helped by a smaller share count as well as better net income.

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of C-PN's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

C-PN's revenue grew 5.6% year-over-year to $85.2B, a solid pace of expansion. This earns a growth score of 41/100.

Leverage

C-PN carries a low D/E ratio of 1.49, meaning only $1.49 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.

Cash Flow

While C-PN generated -$67.6B in operating cash flow, capex of $6.5B consumed most of it, leaving -$74.2B in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

C-PN generates a 6.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 25/100. This is up from 6.1% the prior year.

Piotroski F-Score Weak

3/9

C-PN passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

-4.73x

For every $1 of reported earnings, C-PN generates $-4.73 in operating cash flow (-$67.6B OCF vs $14.3B net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$85.2B

YoY+5.6%

5Y CAGR+2.5%

10Y CAGR+1.1%

C-PN generated $85.2B in revenue in fiscal year 2025. This represents an increase of 5.6% from the prior year.

EBITDA

N/A

Net Income

$14.3B

YoY+12.8%

5Y CAGR+5.3%

10Y CAGR-1.8%

C-PN reported $14.3B in net income in fiscal year 2025. This represents an increase of 12.8% from the prior year.

EPS (Diluted)

$6.99

YoY+17.7%

5Y CAGR+8.2%

10Y CAGR+2.6%

C-PN earned $6.99 per diluted share (EPS) in fiscal year 2025. This represents an increase of 17.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$74.2B

YoY-183.4%

C-PN generated -$74.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 183.4% from the prior year.

Cash & Debt

$349.6B

YoY+26.4%

5Y CAGR+2.5%

10Y CAGR+10.1%

C-PN held $349.6B in cash against $315.8B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

1.75B

YoY-7.2%

5Y CAGR-3.5%

10Y CAGR-5.1%

C-PN had 1.75B shares outstanding in fiscal year 2025. This represents a decrease of 7.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

16.8%

YoY+1.1pp

5Y CAGR+2.2pp

10Y CAGR-5.8pp

C-PN's net profit margin was 16.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.1 percentage points from the prior year.

Return on Equity

6.7%

YoY+0.7pp

5Y CAGR+1.2pp

10Y CAGR-1.0pp

C-PN's ROE was 6.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$13.3B

YoY+435.6%

5Y CAGR+35.3%

10Y CAGR+9.3%

C-PN spent $13.3B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 435.6% from the prior year.

Capital Expenditures

$6.5B

YoY+0.3%

5Y CAGR+13.6%

10Y CAGR+7.4%

C-PN invested $6.5B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.3% from the prior year.

C-PN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$85.2B+5.6%	$80.7B+3.4%	$78.1B+3.6%	$75.3B+4.8%	$71.9B-4.8%	$75.5B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$17.5B
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$29.6B+3.8%	$28.5B-2.4%	$29.2B+9.7%	$26.7B+6.1%	$25.1B+13.1%	$22.2B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$83.1B-7.3%	$89.6B+14.4%	$78.4B+204.4%	$25.7B+222.5%	$8.0B-40.2%	$13.3B
Income Tax	$5.4B+27.6%	$4.2B+19.4%	$3.5B-3.1%	$3.6B-33.2%	$5.5B+115.9%	$2.5B
Net Income	$14.3B+12.8%	$12.7B+37.4%	$9.2B-37.8%	$14.8B-32.4%	$22.0B+98.7%	$11.0B
EPS (Diluted)	$6.99+17.7%	$5.94+47.0%	$4.04-42.3%	$7.00-31.0%	$10.14+114.8%	$4.72

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$19.9B-10.0%	$22.1B+1.9%	$21.7B+0.3%	$21.6B+10.9%	$19.5B-3.7%	$20.2B+0.9%	$20.0B-4.7%	$21.0B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$7.1B-5.4%	$7.5B-2.1%	$7.6B+2.3%	$7.5B+7.8%	$6.9B-1.9%	$7.1B+2.5%	$6.9B-10.2%	$7.7B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$21.0B-3.5%	$21.8B+5.2%	$20.7B+5.2%	$19.7B-7.8%	$21.3B-7.7%	$23.1B+2.7%	$22.5B-1.0%	$22.7B
Income Tax	$1.3B-17.4%	$1.6B+31.5%	$1.2B-11.5%	$1.3B+46.9%	$912.0M-18.3%	$1.1B+6.6%	$1.0B-7.8%	$1.1B
Net Income	$2.5B-34.1%	$3.8B-6.6%	$4.0B-1.1%	$4.1B+42.3%	$2.9B-11.8%	$3.2B+0.7%	$3.2B-4.6%	$3.4B
EPS (Diluted)	N/A	$1.86-5.1%	$1.960.0%	$1.96	N/A	$1.51-0.7%	$1.52-3.8%	$1.58

C-PN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.7T+12.9%	$2.4T-2.4%	$2.4T-0.2%	$2.4T+5.5%	$2.3T+1.4%	$2.3T
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$349.6B+26.4%	$276.5B+6.0%	$260.9B-23.7%	$342.0B+30.5%	$262.0B-15.4%	$309.6B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$19.1B-1.0%	$19.3B-4.0%	$20.1B+2.1%	$19.7B-7.5%	$21.3B-3.9%	$22.2B
Total Liabilities	$2.4T+14.0%	$2.1T-2.8%	$2.2T-0.4%	$2.2T+6.0%	$2.1T+1.4%	$2.1T
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$315.8B+9.9%	$287.3B+0.2%	$286.6B+5.5%	$271.6B+6.8%	$254.4B-6.4%	$271.7B
Total Equity	$212.3B+1.8%	$208.6B+1.5%	$205.5B+2.1%	$201.2B-0.4%	$202.0B+1.3%	$199.4B
Retained Earnings	$215.1B+4.3%	$206.3B+3.7%	$198.9B+2.1%	$194.7B+5.3%	$184.9B+9.9%	$168.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$2.7T+0.6%	$2.6T+0.8%	$2.6T+2.0%	$2.6T+9.3%	$2.4T-3.2%	$2.4T+1.0%	$2.4T-1.1%	$2.4T
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$349.6B+0.4%	$348.1B+3.1%	$337.5B+9.5%	$308.3B+11.5%	$276.5B-8.8%	$303.1B+23.1%	$246.1B-9.8%	$272.7B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$19.1B-0.1%	$19.1B-3.8%	$19.9B+2.3%	$19.4B+0.6%	$19.3B-2.0%	$19.7B-0.1%	$19.7B-1.7%	$20.0B
Total Liabilities	$2.4T+0.6%	$2.4T+0.8%	$2.4T+2.1%	$2.4T+10.0%	$2.1T-3.5%	$2.2T+1.1%	$2.2T-1.3%	$2.2T
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$315.8B0.0%	$315.8B-0.6%	$317.8B+7.5%	$295.7B+2.9%	$287.3B-3.9%	$299.1B+6.7%	$280.3B-1.8%	$285.5B
Total Equity	$212.3B-0.3%	$213.0B-0.1%	$213.2B+0.4%	$212.4B+1.8%	$208.6B-0.2%	$209.1B+0.4%	$208.3B+0.8%	$206.6B
Retained Earnings	$215.1B+0.5%	$214.0B+1.1%	$211.7B+1.3%	$209.0B+1.3%	$206.3B+0.7%	$204.8B+0.9%	$202.9B+1.0%	$201.0B

C-PN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$67.6B-243.9%	-$19.7B+73.2%	-$73.4B-392.9%	$25.1B-46.8%	$47.1B+300.5%	-$23.5B
Capital Expenditures	$6.5B+0.3%	$6.5B-1.3%	$6.6B+16.9%	$5.6B+36.7%	$4.1B+19.5%	$3.4B
Free Cash Flow	-$74.2B-183.4%	-$26.2B+67.3%	-$80.0B-511.6%	$19.4B-54.8%	$43.0B+259.5%	-$26.9B
Investing Cash Flow	-$108.3B-225.5%	$86.3B+1119.6%	-$8.5B+89.4%	-$79.5B+28.3%	-$110.7B-19.8%	-$92.4B
Financing Cash Flow	$238.0B+721.4%	-$38.3B-5675.5%	$687.0M-99.5%	$137.8B+697.6%	$17.3B-92.6%	$233.6B
Dividends Paid	$5.4B+3.3%	$5.2B-0.2%	$5.2B+4.2%	$5.0B-3.8%	$5.2B-2.9%	$5.4B
Share Buybacks	$13.3B+435.6%	$2.5B+25.1%	$2.0B-39.2%	$3.3B-57.2%	$7.6B+159.9%	$2.9B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$26.6B+2314.1%	$1.1B+103.0%	-$36.6B+37.7%	-$58.7B-336.8%	$24.8B+248.7%	-$16.7B+1.7%	-$17.0B-56.6%	-$10.8B
Capital Expenditures	$1.6B+0.9%	$1.6B-7.9%	$1.8B+15.7%	$1.5B-10.1%	$1.7B+8.1%	$1.6B-5.0%	$1.6B+2.3%	$1.6B
Free Cash Flow	$24.9B+4920.9%	-$517.0M+98.7%	-$38.3B+36.3%	-$60.2B-360.6%	$23.1B+226.7%	-$18.2B+2.0%	-$18.6B-49.6%	-$12.4B
Investing Cash Flow	-$49.3B-393.2%	-$10.0B-120.0%	$50.0B+150.5%	-$99.0B-1377.4%	$7.7B-84.9%	$51.4B+318.8%	$12.3B-17.3%	$14.8B
Financing Cash Flow	$25.3B+22.2%	$20.7B+191.8%	$7.1B-96.2%	$185.0B+491.0%	-$47.3B-407.4%	$15.4B+182.1%	-$18.7B-251.7%	$12.4B
Dividends Paid	$1.4B-1.4%	$1.4B+3.2%	$1.3B+0.4%	$1.3B+0.7%	$1.3B-2.1%	$1.3B+7.2%	$1.3B-3.0%	$1.3B
Share Buybacks	$4.5B-10.0%	$5.0B+150.1%	$2.0B+14.2%	$1.8B+80.9%	$968.0M-1.4%	$982.0M+784.7%	$111.0M-73.1%	$413.0M

C-PN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	16.8%+1.1pp	15.7%+3.9pp	11.8%-7.9pp	19.7%-10.8pp	30.5%+15.9pp	14.6%
Return on Equity	6.7%+0.7pp	6.1%+1.6pp	4.5%-2.9pp	7.4%-3.5pp	10.9%+5.3pp	5.5%
Return on Assets	0.5%0.0pp	0.5%+0.2pp	0.4%-0.2pp	0.6%-0.3pp	1.0%+0.5pp	0.5%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	1.49+0.1	1.38-0.0	1.40+0.0	1.35+0.1	1.26-0.1	1.36
FCF Margin	-87.0%-54.6pp	-32.4%+70.1pp	-102.5%-128.3pp	25.8%-34.0pp	59.8%+95.5pp	-35.7%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	12.4%-4.5pp	17.0%-1.6pp	18.6%-0.3pp	18.8%+4.2pp	14.7%-1.4pp	16.0%-0.0pp	16.1%+0.0pp	16.0%
Return on Equity	1.2%-0.6pp	1.8%-0.1pp	1.9%-0.0pp	1.9%+0.5pp	1.4%-0.2pp	1.6%0.0pp	1.5%-0.1pp	1.6%
Return on Assets	0.1%-0.1pp	0.1%-0.0pp	0.1%-0.0pp	0.2%+0.0pp	0.1%-0.0pp	0.1%0.0pp	0.1%-0.0pp	0.1%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	1.490.0	1.480.0	1.49+0.1	1.39+0.0	1.38-0.1	1.43+0.1	1.35-0.0	1.38
FCF Margin	125.4%+127.8pp	-2.3%+174.6pp	-176.9%+101.9pp	-278.9%-397.6pp	118.7%+209.0pp	-90.2%+2.6pp	-92.9%-33.7pp	-59.2%

Frequently Asked Questions

What is C-PN's annual revenue?

C-PN (C-PN) reported $85.2B in total revenue for fiscal year 2025. This represents a 5.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is C-PN's revenue growing?

C-PN (C-PN) revenue grew by 5.6% year-over-year, from $80.7B to $85.2B in fiscal year 2025.

Is C-PN profitable?

Yes, C-PN (C-PN) reported a net income of $14.3B in fiscal year 2025, with a net profit margin of 16.8%.

How much debt does C-PN have?

As of fiscal year 2025, C-PN (C-PN) had $349.6B in cash and equivalents against $315.8B in long-term debt.

What is C-PN's net profit margin?

C-PN (C-PN) had a net profit margin of 16.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is C-PN's return on equity (ROE)?

C-PN (C-PN) has a return on equity of 6.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is C-PN's free cash flow?

C-PN (C-PN) generated -$74.2B in free cash flow during fiscal year 2025. This represents a -183.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is C-PN's operating cash flow?

C-PN (C-PN) generated -$67.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are C-PN's total assets?

C-PN (C-PN) had $2.7T in total assets as of fiscal year 2025, including both current and long-term assets.

What are C-PN's capital expenditures?

C-PN (C-PN) invested $6.5B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does C-PN buy back shares?

Yes, C-PN (C-PN) spent $13.3B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does C-PN have outstanding?

C-PN (C-PN) had 1.75B shares outstanding as of fiscal year 2025.

What is C-PN's debt-to-equity ratio?

C-PN (C-PN) had a debt-to-equity ratio of 1.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is C-PN's return on assets (ROA)?

C-PN (C-PN) had a return on assets of 0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is C-PN's cash runway?

Based on fiscal year 2025 data, C-PN (C-PN) had $349.6B in cash against an annual operating cash burn of $67.6B. This gives an estimated cash runway of approximately 62 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is C-PN's Piotroski F-Score?

C-PN (C-PN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are C-PN's earnings high quality?

C-PN (C-PN) has an earnings quality ratio of -4.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is C-PN?

C-PN (C-PN) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.